Summary
The antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the
clinical association of antiphospholipid autoantibodies (aPL) with a syndrome of hypercoagulability
that can affect any blood vessel, irrespective of type or size. Involvement of larger
vessels, such as arteries or veins, manifests in the form of thrombosis or embolism,
whereas involvement of smaller vessels, including capillaries, arterioles, and venules,
manifests as thrombotic microangiopathy. Virtually any organ in the body, including
the kidney, can be affected. Here, we review the basic principles and recent advances
in our understanding of APS, and discuss the broad spectrum of renal diseases that
have been observed in association with this syndrome. We also discuss the impact that
APS may have on pre-existing renal disease as well as current recommendations for
treatment of APS.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Seminars in NephrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Anti-phospholipid syndrome.N Engl J Med. 2002; 346: 752-763
- Renal involvement in the antiphospholipid syndrome.in: Adu D. Emery P. Madaio M.P. Rheumatology and the kidney. Oxford University Press Inc, New York2001: 132-166
- Development of autoantibodies before the clinical onset of systemic lupus erythematosus.N Engl J Med. 2003; 349: 1526-1533
- The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus.Arthritis Rheum. 2004; 50: 1226-1232
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).J Thromb Haemost. 2006; 4: 295-306
- Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.Arthritis Rheum. 2002; 46: 1019-1027
- Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.Blood. 2003; 101: 1827-1832
- Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.Blood. 2004; 104: 3598-3602
- IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.Blood. 2005; 105: 1540-1545
- Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change.Blood. 2006; 107: 1916-1924
- Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies.Blood. 2003; 101: 3495-3500
- The intrarenal vascular lesions associated with primary antiphospholipid syndrome.J Am Soc Nephrol. 1999; 10: 507-518
- Antiphospholipid syndrome nephropathy in systemic lupus erythematosus.J Am Soc Nephrol. 2002; 13: 47-52
- The expanding spectrum of renal diseases associated with antiphospholipid syndrome.Am J Kidney Dis. 2003; 41: 1205-1211
- Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.Arthritis Rheum. 2004; 50: 2569-2579
- Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis.Am J Kidney Dis. 2004; 43: 28-36
- Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.Lupus. 2003; 12: 530-534
- Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome.Ann Rheum Dis. 2005; 64: 1205-1209
- Long term outcome of catastrophic antiphospholipid syndrome survivors.Ann Rheum Dis. 2003; 62: 530-533
- Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis.Ann Intern Med. 1992; 117: 997-1002
- High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin.Arthritis Rheum. 2001; 44: 1466-1467
- A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.Rheumatology. 2002; 41: 924-929
- APLASA study 2004 update: primary thrombosis prevention in asymptomatic aPL-positive patients with aspirin [abstract].Arthritis Rheum. 2001; 50: S640-S641
- Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis.Lupus. 1996; 5: S16-S22
- The management of thrombosis in the antiphospholipid-antibody syndrome.N Engl J Med. 1995; 332: 993-1007
- Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.Ann Intern Med. 1992; 117: 303-308
- Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment.Ann Rheum Dis. 1993; 52: 689-692
- Comparison of two intensities of warfarin for the prevention of recurrent of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.N Engl J Med. 2003; 349: 1133-1138
- A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).J Thromb Haemost. 2005; 3: 848-853
- New treatments for antiphospholipid syndrome.Rheum Dis Clin North Am. 2006; 32: 129-148
- Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.Arthritis Rheum. 2003; 48: 3272-3280
- New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations.Arthritis Rheum. 2003; 48: 3004-3008
Article info
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
